Leerink Partners Starts Evommune Inc (EVMN) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
Go back to Leerink Partners Starts Evommune Inc (EVMN) at Outperform
December 1, 2025 6:09 AM EST
Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating.
The analyst comments "We are very bullish on EVO756 for CSU given its differentiated mechanism, first-in-class potential, and positive data in CIndU, which meaningfully increases... More
December 1, 2025 6:03 AM EST
Evercore ISI analyst Gavin Clark-Gartner initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating and a price target of $40.00.
The analyst comments "Evommune is an I&I (dermatology to start) focused company with a portfolio of assets. Lead indications are... More
December 1, 2025 5:06 AM EST
William Blair analyst Matt Phipps initiates coverage on Evommune Inc (NYSE: EVMN) with a Outperform rating.
The analyst comments "We are initiating coverage of Evommune with an Outperform rating, based on the potential of the companys first-in-class MRGPRX2 inhibitor EVO756 in the... More
December 1, 2025 3:03 AM EST
Morgan Stanley analyst Judah Frommer initiates coverage on Evommune Inc (NYSE: EVMN) with a Overweight rating and a price target of $36.00.
The analyst comments: "Led by a management team with significant experience bringing anti-inflammatory therapies to patients (e.g., Ebglyss, Cimzia, Rezurock), Evommune is developing... More
